Free tool
FAERS Monitor: Vabomere
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209776 or its brand name (Vabomere, Meropenem, Vaborbactam). Reports on generic versions are filed under their own applications.
Reports
50
Serious
30
60% of reports
Hospitalization
4
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use19
- drug ineffective for unapproved indication7
- death5
- condition aggravated3
- drug ineffective3
- erythema3
- hypersensitivity3
- peripheral swelling3
- rash3
- acute kidney injury2
- blood culture positive2
- creatinine renal clearance increased2
- drug eruption2
- drug resistance2
- headache2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 9 |
| 2019 | 9 |
| 2020 | 8 |
| 2021 | 10 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,109 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| creatinine renal clearance increased | 2 | 1128.9 | 289.8 | 1,264 |
| blood culture positive | 2 | 280.9 | 72.2 | 313 |
| drug ineffective for unapproved indicationSignal | 7 | 53.7 | 27.0 | 312 |
| drug eruption | 2 | 47.5 | 12.2 | 50 |
| drug resistance | 2 | 32.8 | 8.4 | 34 |
| off label useSignal | 19 | 9.1 | 6.4 | 135 |
| peripheral swellingSignal | 3 | 8.2 | 2.7 | 13 |
| hypersensitivitySignal | 3 | 6.8 | 2.3 | 10 |
| erythemaSignal | 3 | 6.1 | 2.0 | 8 |
| acute kidney injury | 2 | 5.5 | 1.4 | 4 |
| condition aggravatedSignal | 3 | 4.2 | 1.4 | 4 |
| rash | 3 | 2.9 | 1.0 | 2 |
| death | 5 | 2.4 | 1.1 | 3 |
| headache | 2 | 1.3 | 0.3 | 0 |
| drug ineffective | 3 | 1.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.